Takuya Miwa

Takuya Miwa

Auto-generated profile, based on publicly available information

Takuya Miwa

Affiliation Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
TSTakehiko Sambe
Takehiko Sambe
TMTakuya Miwa
Takuya Miwa
KYKoichiro Yoneyama
Koichiro Yoneyama
TITakaaki Ishida
Takaaki Ishida
TYTaigi Yamazaki
Taigi Yamazaki
MSMidori Shima
Midori Shima
NXT007 is a bispecific antibody that mimics the cofactor function of activated factor (F)VIII and was engineered by modifying emicizumab. Nonclinical investigations suggested its potential to provide nonhemophilic concentrations of coagulation activity to people with hemophilia A. A first-in-human, single-ascending dose study of NXT007 was conducted in healthy Japanese male adults (part A of the NXTAGE study). To evaluate safety, immunogenicity, pharmacokinetics, and pharmacodynamics of NXT007. Forty participants were enrolled across 5 cohorts and randomized to receive a single subcutaneous injection of NXT007 (n = 6 per cohort; 0.0018, 0.0054, 0.018, 0.054, or 0.18 mg/kg) or placebo (n = 2 per cohort). There were no dose-dependent increases in the incidence of adverse events, and no thrombotic events or injection-site reactions were reported. One serious adverse event of erythema was reported in a participant who received NXT007 0.0054 mg/kg, and its causality to NXT007 could not be ruled out. Nine participants developed anti-NXT007 antibodies; all were considered to be associated with faster clearance of NXT007 without impacting safety. NXT007 exposure increased dose-dependently but less than dose proportionally. The elimination half-life of NXT007 was approximately 10 weeks in antidrug antibody-negative participants. With ex vivo neutralization of endogenous FVIII in plasma samples, activated partial thromboplastin time was shortened, and thrombin generation was promoted in a dose-dependent manner. A single subcutaneous injection of NXT007 was well tolerated without occurrence of thrombotic events. The long half-life, pharmacological effect, and safety profile supported study progression to the subsequent multiple ascending dose parts of the NXTAGE study in people with hemophilia A.

7 May 2026 in Blood
Verified
Journal Article
Open access
PDF file
KNKeiji Nogami
Keiji Nogami
CYChur-Woo You
Chur-Woo You
YPYoung Shil Park
Young Shil Park
YCYeu-Chin Chen
Yeu-Chin Chen
MSMing ching Shen
Ming ching Shen
MSMidori Shima
Midori Shima
NXT007 is a next-generation, activated factor VIII (FVIIIa)–mimetic bispecific antibody under investigation in the phase 1/2 NXTAGE trial. Here, we report the primary analysis of the multiple-ascending-dose Part B study in people with hemophilia A (PwHA). Eligible participants were men with severe HA without FVIII inhibitors. Four dose cohorts (B1-B4) were planned, with NXT007 administered subcutaneously at maintenance doses of 0.072 mg/kg, 0.28 mg/kg, 0.70 mg/kg, and 1.08 mg/kg, respectively, every 4 weeks. Primary end points were safety (adverse events [AEs] and serious AEs [SAEs]), tolerability, pharmacokinetics, pharmacodynamics, and efficacy; secondary end points included incidence of anti-drug antibodies (ADAs). Participants in cohorts B1 (n = 10), B2 (n = 6), B3 (n = 6), and B4 (n = 8) had received NXT007 for a median (minimum to maximum) of 114.1 (29-140), 96.4 (88-112), 58.1 (52-72), and 22.2 (4-28) weeks, respectively. Two participants discontinued treatment: NXT007-unrelated AE (n = 1) and complete loss of NXT007 exposure due to ADAs (n = 1). Participants’ plasma NXT007 concentration showed a dose-dependent increase, and predicted FVIII-equivalent activity reached a nonhemophilic level (≥40 IU/dL) in B2 onward. NXT007 had a favorable safety profile at all doses. Most AEs were mild/moderate and all 3 SAEs were considered unrelated to NXT007. Mean annualized treated bleed rates were 1.48 (B1), 0.28 (B2), 0.00 (B3), and 0.00 (B4). Two participants had pharmacokinetics-affecting NXT007 ADAs, including the B1 participant who discontinued treatment. NXTAGE Part B demonstrates that NXT007 could provide nonhemophilic coagulation activity in PwHA, with a less burdensome dose regimen than currently available therapies. This trial was registered at Japan Registry of Clinical Trials as jRCT2080224835.

23 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTakuya Miwa
Takuya Miwa
KMKazuma Mii
Kazuma Mii
RCRyouichi Chatani
Ryouichi Chatani
YSYasuo Sugitani
Yasuo Sugitani
Introduction: Wearable accelerometer devices are now widely used in both research and daily life settings. This study aimed to compare the accuracy of three commercially available consumer-grade activity monitors with the medical-grade ActiGraph device in a free-living setting in Japan. Methods: Thirty-six office workers were enrolled and provided with an ActiGraph. Data were analyzed from participants who also wore Apple Watch ( n = 21), Fitbit ( n = 22), and Oura Ring ( n = 5) over a 3-week period. Step count, physical activity energy expenditure (PAEE), and moderate-to-vigorous physical activity (MVPA) data were collected from all devices. Data were analyzed using correlation coefficients, mean differences, and Bland–Altman plots. Results: ActiGraph data confirmed comparable physical activity levels across the participant subgroups, ensuring a valid basis for the subsequent inter-device comparisons. Step counts were largely consistent across devices, with Apple Watch and Oura Ring measurements within 10% of ActiGraph measurements (mean percentage differences 2.12% and −6.24%, respectively), while the Fitbit overestimated step count by 18.00%. MVPA showed greater variability, with Apple Watch and Oura Ring underestimating by 46.22% and 11.64% respectively, whereas the Fitbit showed minimal mean difference (0.62%). PAEE showed the largest discrepancies, with Apple Watch and Fitbit overestimating by 25.91% and 139.19% respectively, and Oura Ring underestimating by 16.87%. Correlation coefficients were strong for step counts ( r = 0.84–0.92) but lower for MVPA and PAEE across all devices. Bland–Altman analysis revealed proportional bias in the Fitbit’s PAEE and the Apple Watch’s MVPA, with errors increasing at higher activity levels. Conclusion: Step counts were largely consistent with the ActiGraph for most devices; however, the Fitbit showed a notable overestimation. However, the ability of those devices to accurately measure MVPA and PAEE appeared to be more limited, particularly at higher activity levels. These findings underscore that the selection of a consumer-grade wearable for research or clinical use must be carefully guided by the specific metric of interest. However, the findings for the Oura Ring should be interpreted with caution due to the small sample size.

20 January 2025 in Chemistry – A European Journal
Verified
Journal Article
Closed access
TMTakuya Miwa
Takuya Miwa
AYAkiko Yumoto
Akiko Yumoto
STSeiichi Tada
Seiichi Tada
SKShin‐Woong Kim
Shin‐Woong Kim
NMNoriko Minagawa
Noriko Minagawa
TUTakanori Uzawa
Takanori Uzawa